We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Barr Pharmaceuticals and Kos Pharmaceuticals have reached a settlement agreement under which Barr won’t launch generic versions of Kos’ Niaspan or Advicor until 2013, unless other generic versions of the cholesterol-lowering products enter the market first.
Mergers between brand and generic firms are becoming an increasingly attractive option in today’s business climate, according to an industry expert, who said such partnerships can provide synergies that neither sector can achieve on its own.
GlaxoSmithKline (GSK) has finalized a deal to market a prescription version of Roche’s leading weight-loss drug Xenical in the U.S., the companies announced April 12.
The FTC submitted a second request to Novartis Pharmaceuticals last week for additional information about its pending acquisitions of German generic drugmaker Hexal AG and U.S. generic firm Eon Labs.
Barr Laboratories is taking the plunge into the follow-on biologics market, announcing March 30 that it is partnering with Croatian biopharmaceutical firm PLIVA to develop its first biogeneric product.
Barr Laboratories is taking the plunge into the follow-on biologics market, announcing March 30 that it is partnering with Croatian biopharmaceutical firm PLIVA to develop its first biogeneric product.
Johnson & Johnson (J&J) has agreed to acquire Lexington, Mass.-based TransForm Pharmaceuticals, which specializes in the discovery of molecules used in making Rx drugs, for $230 million.
MIV Therapeutics (MIVT) has executed a letter of intent to acquire Sahajanand Medical Technologies (SMT) in order to form a drug-eluting stent company that would use MIVT’s next generation line of advanced biocompatible coatings with SMT’s stents, the companies said last week.